vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与Planet Labs PBC（PL）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是Planet Labs PBC的1.9倍（$152.6M vs $81.3M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs -72.8%，领先107.4%），Planet Labs PBC同比增速更快（32.6% vs 7.6%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $1.9M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 17.5%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
Planet Labs PBC（常简称为Planet）是总部位于美国加利福尼亚州旧金山的上市地球影像企业，核心目标是实现全球范围的每日成像，以此监测地表变化、精准识别相关趋势，为多行业的地理数据分析需求提供可靠的数据支持。
CPRX vs PL — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $81.3M |
| 净利润 | $52.7M | $-59.2M |
| 毛利率 | 82.9% | 57.3% |
| 营业利润率 | 40.5% | -22.6% |
| 净利率 | 34.5% | -72.8% |
| 营收同比 | 7.6% | 32.6% |
| 净利润同比 | -5.8% | -194.7% |
| 每股收益（稀释后） | $0.40 | $-0.19 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $81.3M | ||
| Q3 25 | $148.4M | $73.4M | ||
| Q2 25 | $146.6M | $66.3M | ||
| Q1 25 | $141.4M | $61.6M | ||
| Q4 24 | $141.8M | $61.3M | ||
| Q3 24 | $128.7M | $61.1M | ||
| Q2 24 | $122.7M | $60.4M | ||
| Q1 24 | $98.5M | $58.9M |
| Q4 25 | $52.7M | $-59.2M | ||
| Q3 25 | $52.8M | $-22.6M | ||
| Q2 25 | $52.1M | $-12.6M | ||
| Q1 25 | $56.7M | $-35.2M | ||
| Q4 24 | $55.9M | $-20.1M | ||
| Q3 24 | $43.9M | $-38.7M | ||
| Q2 24 | $40.8M | $-29.3M | ||
| Q1 24 | $23.3M | $-30.1M |
| Q4 25 | 82.9% | 57.3% | ||
| Q3 25 | 84.7% | 57.6% | ||
| Q2 25 | 85.9% | 55.2% | ||
| Q1 25 | 87.3% | 62.1% | ||
| Q4 24 | 84.7% | 61.2% | ||
| Q3 24 | 85.0% | 52.9% | ||
| Q2 24 | 87.4% | 52.4% | ||
| Q1 24 | 87.3% | 55.2% |
| Q4 25 | 40.5% | -22.6% | ||
| Q3 25 | 44.7% | -24.5% | ||
| Q2 25 | 45.2% | -34.4% | ||
| Q1 25 | 44.8% | -31.5% | ||
| Q4 24 | 44.3% | -36.9% | ||
| Q3 24 | 39.6% | -64.8% | ||
| Q2 24 | 44.2% | -57.2% | ||
| Q1 24 | 27.5% | -57.6% |
| Q4 25 | 34.5% | -72.8% | ||
| Q3 25 | 35.6% | -30.8% | ||
| Q2 25 | 35.6% | -19.1% | ||
| Q1 25 | 40.1% | -57.1% | ||
| Q4 24 | 39.4% | -32.8% | ||
| Q3 24 | 34.1% | -63.3% | ||
| Q2 24 | 33.2% | -48.5% | ||
| Q1 24 | 23.6% | -51.1% |
| Q4 25 | $0.40 | $-0.19 | ||
| Q3 25 | $0.42 | $-0.07 | ||
| Q2 25 | $0.41 | $-0.04 | ||
| Q1 25 | $0.45 | $-0.12 | ||
| Q4 24 | $0.44 | $-0.07 | ||
| Q3 24 | $0.35 | $-0.13 | ||
| Q2 24 | $0.33 | $-0.10 | ||
| Q1 24 | $0.19 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $443.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $349.6M |
| 总资产 | $1.1B | $1.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $443.3M | ||
| Q3 25 | $689.9M | $181.1M | ||
| Q2 25 | $652.8M | $133.5M | ||
| Q1 25 | $580.7M | $118.0M | ||
| Q4 24 | $517.6M | $139.0M | ||
| Q3 24 | $442.3M | $148.3M | ||
| Q2 24 | $375.7M | $107.4M | ||
| Q1 24 | $310.4M | $83.9M |
| Q4 25 | $954.3M | $349.6M | ||
| Q3 25 | $920.2M | $435.7M | ||
| Q2 25 | $856.0M | $444.8M | ||
| Q1 25 | $794.3M | $441.3M | ||
| Q4 24 | $727.6M | $464.6M | ||
| Q3 24 | $660.9M | $473.2M | ||
| Q2 24 | $608.7M | $500.3M | ||
| Q1 24 | $561.4M | $518.0M |
| Q4 25 | $1.1B | $1.1B | ||
| Q3 25 | $1.1B | $696.4M | ||
| Q2 25 | $971.9M | $658.4M | ||
| Q1 25 | $908.9M | $633.8M | ||
| Q4 24 | $851.4M | $630.8M | ||
| Q3 24 | $772.0M | $658.4M | ||
| Q2 24 | $706.4M | $674.6M | ||
| Q1 24 | $646.7M | $702.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $28.6M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $1.9M |
| 自由现金流率自由现金流/营收 | 29.4% | 2.3% |
| 资本支出强度资本支出/营收 | 0.0% | 32.9% |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | $40.7M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $28.6M | ||
| Q3 25 | $32.4M | $67.8M | ||
| Q2 25 | $71.3M | $17.3M | ||
| Q1 25 | $60.0M | $-6.3M | ||
| Q4 24 | $70.9M | $4.1M | ||
| Q3 24 | $72.9M | $-7.9M | ||
| Q2 24 | $64.1M | $-4.3M | ||
| Q1 24 | $31.9M | $-6.8M |
| Q4 25 | $44.9M | $1.9M | ||
| Q3 25 | — | $47.5M | ||
| Q2 25 | $71.3M | $9.2M | ||
| Q1 25 | — | $-17.9M | ||
| Q4 24 | $70.8M | $-3.6M | ||
| Q3 24 | $72.6M | $-23.0M | ||
| Q2 24 | $64.1M | $-14.2M | ||
| Q1 24 | $31.7M | $-15.7M |
| Q4 25 | 29.4% | 2.3% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | 48.6% | 13.9% | ||
| Q1 25 | — | -29.1% | ||
| Q4 24 | 49.9% | -5.8% | ||
| Q3 24 | 56.4% | -37.6% | ||
| Q2 24 | 52.3% | -23.6% | ||
| Q1 24 | 32.2% | -26.7% |
| Q4 25 | 0.0% | 32.9% | ||
| Q3 25 | 0.0% | 27.6% | ||
| Q2 25 | 0.0% | 12.3% | ||
| Q1 25 | 0.0% | 18.9% | ||
| Q4 24 | 0.1% | 12.5% | ||
| Q3 24 | 0.2% | 24.8% | ||
| Q2 24 | 0.0% | 16.4% | ||
| Q1 24 | 0.2% | 15.1% |
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | — | ||
| Q2 25 | 1.37× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.57× | — | ||
| Q1 24 | 1.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
PL
| Defense And Intelligence | $49.4M | 61% |
| Civil Government | $18.8M | 23% |
| Commercial | $13.1M | 16% |
